This research project is a first step towards a larger goal to understand in more depth what is required structurally to form the right policy incentives under UN frameworks to unlock value in the health sector with respect to sharing of data, algorithms and capabilities for the broader good, particularly focusing on high-impact Artificial Intelligence (AI) use-cases. One proposition to achieve this is using the UN Guiding Principles on Business on Human Rights as basis for policy recommendations, and further strengthening the moral foundation by investigating biomedical ethics related questions. Also, current ongoing discussions with regards to Sustainable Development Goals (SDGs) in the pharmaceutical sector are indicating that corporations are particularly challenged with Social- & Governance-Scoring related questions, and investors expressed worries that their portfolio companies might will face headwinds in sustaining their legal and social license to operate in the long-run. In this regard, for instance, one point of criticism from policy makers is the concentration of extraordinary AI capabilities among a few large and/or specialized corporations, besides other ethical issues that impact societies at large. We believe that business models, AI ethics, financing and policy related questions for the health sector are interwoven and require a holistic approach to converge to a common agreement between various stakeholders, and that international UN frameworks and institutions could provide a platform to discuss the right incentive mechanisms with regards to digital governance, achieving the ultimate goal for better common goods outcomes.